The value of a test for islet cell cytoplasmic antibodies together with a test for GAD6s antibodies to predict the subsequent development of diabetes over a period of 11.5 years was assessed in an open childhood population comprising 2,805 individuals. A single serum sample was obtained from each individual between 1975 and 1977 and screened for islet cell cytoplasmic antibodies for which eight individuals were positive (0.29 %). During the average follow-up period of 11.5 years, four of eight islet cell antibody positive and three islet cell antibody negative individuals developed clinical diabetes. Sera from all individuals, who were islet cell antibody positive and/ or developed diabetes (total of 11) and from 100 randomly selected control subjects were analysed for GAD65 antibodies. Six of eight islet cell antibody positive individuals were GAD65 antibody positive including all four who subsequently developed IDDM. Furthermore, one of the three islet cell antibody negative individuals who developed IDDM was GAD65 antibody positive both in 1976 and in 1989. Thus, a positive test for GAD6s antibodies alone correctly predicted diabetes in five of seven children, who developed the disease. Only one of the children, who developed diabetes was positive for insulin autoantibodies and this individual was also positive for islet cell cytoplasmic antibodies and GAD65 antibodies. One of the 100 control subjects was positive for GAD6s antibodies (1%). The results suggest that a single GAD65 antibody test may have a higher sensitivity for predicting IDDM than a test for islet cell cytoplasmic antibodies, but that a combined positive test for both antibodies increases the specificity for predicting IDDM over a period of 11.5 years. [Diabetologia (1994) 37: 917-924] Key words GAD65 antibodies, islet cell cytoplasmic antibodies, predictive value, IDDM in childhood.
and insulin dependency. A major goal of diabetes research is to develop immune interventions that block or otherwise interfere with the destruction of beta cells and the development of clinical diabetes. Concomitant with this goal is the necessity for methods for early accurate identification of susceptible individuals [5] . Antibody assays that detect early signs of humoral autoimmunity associated with beta-cell destruction are obvious candidates for this purpose. Furthermore, susceptibility to develop diabetes is associated with certain MHC-class II haplotypes [6] and analysis of both HLA haplotypes and autoantibodies provide a test of high predictive value in family members of IDDM patients [3, 7] . Since most new cases of [DDM involve individuals without a first degree relative with the disease [8, 9] , predictive meth-ods need to be easily applicable to analyses of the general population.
The classic method to analyse islet cell autoantibodies (ICA) is by immunohistology using freshfrozen pancreatic sections. The ICA assay is however difficult to standardize [10] . A better method for a standardized analysis of early humoral responses in IDDM might involve a rapid and quantitative assay using a target antigen of humoral autoimmunity in IDDM such as insulin [11] , or the GAD65 autoantigen [12] .
Insulin autoantibodies (IAA's) are only detected in up to 50 % of newly-diagnosed patients and are most frequent in very young patients (< 5 years of age) [13] . IAA's alone have a limited predictive value and are not suitable as a marker to replace ICA's [5, 14, 15] .
Incidence of 64 kDa or GAD65 autoantibodies in the pre-diabetic period and at clinical onset of IDDM measured by immunoprecipitation of 35S-methionine labelled human islet cell protein is 75-90 % [4, 16] . Following identification of the 64 kDa protein as the smaller form of the enzyme glutamic acid decarboxylase [12, 17] , now called GAD65 , several assays were developed and standardization is now beginning (1st GAD antibody workshop was held under the auspices of the 12th International Immunology of Diabetes Workshop, Orlando, April 1993). GAD65 antibodies precede IDDM by several years and are detected concomitantly with, and sometimes before, ICA and IAA [4, 16, 18] .
GAD6s is a cytoplasmic protein and is amongst the target antigens of ICA's [19, 20] . Purified GAD65 however does not block all ICA reactivity in some sera [20] and the ICA reactivity is likely to involve other target molecules. Furthermore, sera that immunoprecipitate GAD6s do not always react with the protein by immunohistology and are therefore negative in the ICA assay [16, 21] . In most IDDM patients, ICAs only stain frozen and not fixed sections of human pancreas. Thus, ICA epitopes are dependent on conformation of the relevant antigen [22] . Similarly diabetes associated epitopes in the GAD6s molecule are predominantly conformational and only the sera of very few patients recognize a linear epitope in the protein [12, 19] .
In addition to GAD6s, GAD is expressed as a second non-allelic form, GAD67 in neurons [23] and in rat and mouse beta cells [24] . Human islets only express the GAD6s protein [24, 25] and the incidence of GAD67 antibodies in IDDM is low [26, 27] . GAD67 does not seem to have an independent role as an autoantigen in IDDM. Rather this protein only seems to be recognized in cases where the immune response to GAD65 involves recognition of epitopes that cross-react in the two proteins [27] .
Previous studies have suggested that islet ICA measured by immunohistology are of insufficient specificity to serve as a single marker of susceptibility [5, H.-J. Aanstoot et al.: GAD65 antibodies in a childhood population 28, 29] . One study of the predictive value of ICA in a Dutch childhood population [30] without emphasis on families of diabetes patients, found an incidence of 0.29 %, which is close to the incidence of IDDM in The Netherlands. This study used a human pancreas which was prepared with a very short ischaemia time resulting in frozen sections that enabled ICA analyses of very high specificity and sensitivity [30] . All the ICA-positive subjects had complement fixing ICA (CF-ICA) and the antibodies preceded the clinical onset of nonfamilial diabetes in some individuals by several years [30] . The predictive value of positive CF-ICA test on a single occasion to predict the development of IDDM in a subsequent 11.5-year follow-up period was 50 %. The sensitivity of CF-ICA to predict IDDM was 57 %.
The present study analysed GAD65 autoantibodies in all individuals in this population who were either CF-ICA positive or developed IDDM during the 11.5-year follow-up period, as well as in 100 randomly-selected subjects who remained healthy during this period. Although it was not possible to analyse GAD65 autoantibodies in the whole population with the methodology currently available, we have calculated the potential of a combined test for CF-ICA followed by GAD65 antibody analysis to predict diabetes in a childhood population at large, based on a single serum sample per child with a minimum follow-up of 10 years. The study shows that the combination of a positive test for CF-ICA and for GAD65 antibodies yields a strong predictive value for subsequent development of IDDM in individuals who are not relatives of IDDM patients and is more specific than a single positive test for either antibody.
Materials and methods
Description of the population: The population studied has been described in detail [30] . Briefly, 4860 schoolchildren aged 5-19 years of age from one township in The Netherlands participated in a longitudinal study on risk factors for cardiovascular and chronic diseases. The data collected included a history on IDDM. Serum was collected from these children between 1975 and 1977. Serum samples of 3383 individuals were available for ICA analysis. In 1988, a questionnaire was sent to all subjects for whom family data on diabetes were available. The three criteria of having a complete first-degree family history of IDDM, a stored serum sample and an adequate response to the questionnaire by the end of an average follow-up time of 11.5 years were fulfilled by 2805 children. CF-ICA's and IANs were measured in this population and their predictive value analysed [30] . A second serum sample was obtained in 1989 from 10 of the 11 individuals, who were ICA positive in 1975-1977 and/or who developed IDDM in the interim period.
Measurement of GAD6s antibodies using rat islets: Autoantibodies to GAD65 expressed in rat islets were measured by immunoprecipitation of Triton X-114 (Calbiochem, San Diego, Calif., USA) detergent phase purified cytosolic protein fraction [12] . Immune complexes were analysed by SDS-PAGE using 10 % slab gels. Gels were processed for fluorography [31] . Fluorograms were obtained by 2, and 4 week exposure of each gel and analysed visually by three independent observers, who did not know the sample identity and scored positive if the GAD6s ct//~ doublet was visible. A quantitative estimate of GAD65 in positive immunoprecipitates was obtained by densitometric scanning of autoradiograms using a BioRad model 620 Video Densitometer with 1D Analyst II and version 3.10 software (BioRad, Richmond, Calif., USA) and a control serum which is used as a positive standard for quantitative analyses of GAD65 autoantibodies and has an arbitrary value set at 10 [21] . GAD6s antibody values in other sera were calculated from integrated peak areas by the formula: 10 • (value for unknown serum -value for negative control serum) / (value for positive control serum -value for negative control serum). The prevalence of GAD6s antibodies in newly-diagnosed IDDM patients using this method (immunoprecipitation of Triton X-114 detergent phase purified rat islet cytosolic proteins) (n =73) is 82.2 %. The prevalence in healthy control individuals (n =69) is 1.4 %.
Measurement of GAD65 antibodies using recombinant GAD o5 expressed in COS-cells: The eucaryotic expression vector pMT2
(kindly donated by Dr. R. Kaufman, Genetics Institute, Boston, Mass., USA) was used for transient expression of rat GAD65 in COS-7 cells. O!igonucleotide directed mutagenesis was used to change the sequence surrounding the translation initiation site of GAD65 into the Kozak consensus sequence [32] for optimum expression in mammalian cells before subcloning into the pMT2 vector. A 2.4 kilobase cDNA fragment containing the coding region of rat GAD65 was released from a cDNA clone (kindly donated by Dr. A.Tobin, University of California Los Angeles, Calif., USA) by EcoR I restriction enzyme digestion and inserted into the EcoR I site of pMT2. The resulting plasmid was named pMT2-rGAD6s-10. This clone was transfected into COS-7 cells (American Tissue Culture Collection, ATCC) using lipofectamine (GIBCO/BRL Grand Island, New Y., USA) according to the manufacturer's instructions. Forty eight hours after transfection cells were labelled with 400 ~Ci of 35S methionine (Amersham SJ-1515, Arlington Heights, Ill,, USA) per 10-cm plate. After labelling, cells were washed three times in an ice-cold harvest buffer (10 mmol/1 Hepes/NaOH pH 7.4, 150 mmol/1 NaC1, 10 mmol/1 benzamidine/HC1, 0.1 mmol/1 p-ehloromercuriphenyl sulphonic acid (PCMBS), and 0.1 mmol/1 phenylmethylsulphonyl fluoride (PMSF). All following procedures were performed at 4 ~ The cells were collected by scraping into 1 ml of HEAP buffer (10 retool/1 Hepes NaOH, pH 7.4, 1 mmol/l MgC12, 0.2 mmolfl pyridoxal-5-phosphate, ! retool/1 aminoethylisothiouronium bromide hydrobromide) containing 0.1 mmol/1 PMSF and 1% Triton X-114, and extracted for i hour by repeated pipetting through a bent pipette tip. The extract was cleared by ultra centrifugation at 265,000 x g for i h in a Beckman TLA-100 ultracentrifuge with a TLA 100.3 rotor (Beckman, Fullerton, Calif., USA). The supernatant was subjected to a temperature induced TX-114 phase separation [33] . The detergent phase, containing the soluble amphiphilic GAD65 , was collected and diluted in HEMAP buffer (HEAP buffer with i mmol/1 MgC12). Aliquots containing 200,000 cpm per immunoprecipitate were precleared using normal human serum. Precleared aliquots were incubated with test sera for 16 h in a total volume of 220 !~1. Immunecomplexes were isolated by incubation for I h with protein-A Sepharose (Pharmacia, Piscataway, New J., USA) which had been coated with cold COS-7-cell lysate to minimize non-specific absorption. Immunocomplexes bound to Protein-A Sepharose were washed 5 times in IMPwashing buffer (10 mmol/1 Hepes NaOH, pH 7.4, 150 mmol/1 NaC1, 10 mmol/1 benzamidine/HC1, 0.5 mmol/1 methionine, 5 mmol/1 EDTA, 0.1% bovine serum albumin) and once in au-toclaved H20. Immunocomplexes were eluted from Protein-A Sepharose, analysed by SDS-PAGE and processed for fluorography. Fluorograms were obtained from a 2-and 4-week exposure of each gel, analysed for a positive GAD6~ct/fl signal and quantitated as described above. In addition quantitative analyses of GAD65 on gels were performed using a model 425 Phospor-Imager (Molecular Dynamics, Sunnyvale, Calif., USA) following both 1-and 3-day exposure. The results of the Phosphor-Imager analyses and the densitometric analyses were similar except that the former measurement is linear over a longer range. Using the COS-cell material the prevalence of GAD65 antibodies is 80.8 % in newly-diagnosed IDDM patients (n=182) and 2.2% in healthy control individuals (n =271). This assay yielded 100% sensitivity and 100% specificity in the first GAD antibody workshop.
Sera analysed for GAD65 antibodies by both assays included all seven individuals who developed IDDM, the four individuals who were ICA-positive, but did not develop diabetes, and three control subjects. Ninety seven age-matched control subjects were analysed using the COS-cell assay only.
HLA haplotyping, CF-ICA analyses, and IAA analyses: HLA haplotyping was performed as described by Giphart and coworkers [34] . The ICA assay was described earlier [30] . The same pancreas, which gave an unusually low background and high specificity in the analyses of the 1975-1977 samples [30] , were used for analyses of the 1989 samples. The Juvenile Diabetes Foundation world standard serum for ICA analyses and containing 80 JDF units, was positive on this pancreas up to a dilution of 1 : 256. Dilution of this standard serum showed a strict linear titration curve, 0.625 JDF units corresponding to a titre of 1 : 2. ICA levels in samples were expressed in reciprocal titres rather than JDF titres because the calculated JDF titres are lower than the positive range for analyses using pancreases of lower quality. This assay participates in the International Diabetes Workshops on ICA proficiency. IAA were measured in all seven individuals who developed IDDM, and in the four individuals who were ICA positive, but did not develop diabetes, using both an ELISA assay [35] , and a radioimmunoprecipitation assay [11] . Both assays participate in the International Diabetes Workshops on IAA proficiency. A positive value is defined as larger than 3 x a SD value obtained for 100 control individuals amongst whom none are positive in the radioimmunoprecipitation assay and 3.7 % are positive in the ELISA assay. The corresponding values for newly-diagnosed IDDM patients are 15 % (n =115) and 13 % (n =84) in the two assays, respectively.
Results
The GAD65 antibody assay: The analyses of GAD65 autoantibodies in this study included:
1)immunoprecipitation of the soluble hydrophobic form of GAD65 partially purified from rat islets [12, 17] ( Fig. 1 A and C) , and 2) immunoprecipitation of partially purified membrane and soluble forms of recombinant GAD65 expressed in COS-7 cells (Fig. 1 B  and D) . The first assay is a derivative of the standard immunoprecipitation assay using GAD65 expressed in islet cells [4, 21] but uses only the hydrophobic soluble fraction of islets. Since very few cytosolic proteins in rat islets, except GAD65 , are hydrophobic, the use of this fraction results in a very low background in im- munoprecipitates. Both methods are equally sensitive in detecting GAD65 autoantibodies in low-high titre sera. However, the first method is more sensitive for analyses of very low titre sera, because it has a better signal to noise ratio and allows specific detection of very low levels of the characteristic ~ and fi doublet of GAD65 in immunoprecipitates [31] by long exposure of autoradiograms. This enhanced sensitivity was necessary for detection of GAD65 antibodies in the baseline serum from subject number 11 ( Fig. 1 C) and the 1989 serum from subject number 4 ( Fig. 2 ) in long exposure of fluorograms. By comparison the COS-7 cell assay did not detect a GAD65 signal above background in immunoprecipitates with those two samples after long exposures. Both assays however detected GAD6s antibodies in the same individuals in either earlier (subject n u m b e r 4 ) or later (subject number 11) samples (Figs. 1 and 2 , Table 1 ). Table 1) were positive, including all four who subsequently developed IDDM. One of those individuals (number 3), was the only IAA-positive individual by the ELISA assay whereas none were positive by the radio immunoprecipitation assay.
Prevalence of IDDM in the follow-up period:
Among the three ICA-negative children who developed I D D M during the follow-up period, two (number 9 and 10. Fig. 1 A-C; Table 1 ) were also negative for GAD65 antibodies in the serum sample collected between 1975-1977. One subject (number 11, Fig. 1, Table 1 ) was scored negative for GAD65 antibodies based on a short exposure of fluorograms of rat islet immunoprecipitates and COS-7 cell immunoprecipitates (Fig. 1 A) . However, prolonged exposure of rat islet immunoprecipitates clearly revealed that this serum immunoprecipitated the characteristic a and fi doublet of the GAD65 autoantigen (Fig. 1 C) . Amongst 100 healthy ICA-negative subjects included in the GAD65 antibody analyses, one individual, a 16-year-old female, was GAD65-antibody-positive (GAD65 antibody index 3.5).
GAD65 antibody status 12-13 years after the initial sampling:
In 1989 sera were collected from all the eight subjects who were ICA-positive at baseline (number 1-8) and from two of the ICA-negative subjects (number 10 and 11) who had developed IDDM. Subject number 9 was not available for testing in 1989. Sera were assayed for GAD65 autoantibodies and ICA (Fig.lD, 
Longitudinal analyses of lCA and GAD antibodies in two subjects:
Two girls (subjects number 3 and 4) also participated in a cohort study for general health risk factors. Each developed IDDM during the period of this study. Both were reexamined every 12 months. ICA and GAD65 antibody titres were retrospectively analysed and compared in the sequential sera (Fig. 2) . Subject 3 remained weakly positive for GAD65 antibodies throughout the 11-year observation period, which included 5 years following the clinical onset of IDDM. Subject 4 showed a continual decrease from a high GAD65 antibody immunoreactivity during the 13-year observation period. She was weakly positive in the last sample, which was obtained 9 years following clinical onset of IDDM. A similar pattern was observed for ICA. 
Sensitivity of individual and combined assays to predict IDDM:
The sensitivity of a combined antibody assay positive for both ICA and GAD65 antibodies in a single sample to predict IDDM in the seven children who had a clinical onset during the follow-up period was 57 % (4 of 7; CL: 18-90 %) or the same as for ICA alone. The sensitivity of a GAD65 antibody assay alone to predict IDDM in the seven children was 71% (5 of 7; CL: 29-96 %). The sensitivity of a combined assay positive for both ICA and IAA in a single sample to predict IDDM in the seven children, who had a clinical onset during the follow-up period was 14 % (1 of 7; CL: 1-53 %) or the same as the sensitivity of IAA antibodies alone and several fold lower than the sensitivity of the ICA and GAD65 antibody assays alone.
Predictive value of ICA combined with GAD65 autoantibodies: The lack of GAD65 antibody data for all but 111 of the 2.805 children constituting this study base excludes the calculation of a positive and a negative predictive value and a specificity for GAD65 antibodies alone [36, 37] . However, these parameters can be calculated for a combined ICA and GAD65 antibody assay. Thus, the probability of a child acquiring IDDM within 10 years if both autoantibodies were positive at baseline (positive predictive value) was 67 % (4 of 6; CL Predictive value of ICA combined with IAA: The positive predictive value for a combined ICA and IAA assay was 100 % (1 of 1), which was higher than for a combined assay for ICA and GAD65 antibodies. Similarly the specificity of the combined assay was i00 % (2798 of 2798; CL: 99.86-100.00 %). The probability of absence of clinical IDDM among subjects not positive for both ICA and IAAwas 99.79 % (2798 of 2804; CL: 99.53-99.92 %) compared to the negative predictive value for ICA alone and ICA combined with GAD65 antibodies of 99.89 %.
HLA-tissue typing:
HLA DR and DQ haplotypes are shown in Table 1 . Subjects 1-5 and 10 were HLA DR3 and/or DR4 positive. All the HLA DR4-positive subjects had the DQw8 (DQBI*0302) allele which is present in 95 % of DR4-positive IDDM patients vs 50 % of DR4-positive control subjects [6, 38] . Subjects 7, 8 and 11 had the DR1, DQw5 (DQBI*0501) H.-J. Aanstoot et al.: GAD65 antibodies in a childhood population haplotype, which is associated with a weakly increased risk of IDDM [38] . Subject 6 was positive for the HLA-DR2, DQw6 (DQBI*0602) haplotype, which is negatively associated with IDDM [39] . Subject number 9 was not available for HLA-typing. The positive control individual did not consent to HLA-typing.
Discussion
We have assessed the predictive value of a combined assay for ICA and GAD65 antibodies in a single serum sample and with an average follow-up of 11.5 years in a low-risk childhood population. The low prevalence of ICA in the 2805 individuals analysed in this study (0.29 %) has been attributed to the high specificity and sensitivity of the pancreas used for the ICA analyses [30] [44] respectively in childhood populations. The results presented here suggest that even compared to unusually specific ICA measurements alone, ICA analyses supplemented with GAD6s autoantibody analysis are likely to have increased specificity in predicting IDDM. Of a normal low-risk population of 2805 children who represented the study base for these analyses, four children would be incorrectly predicted to become diabetic in a 10-year follow-up by a single positive test for CF-ICA alone. This number was decreased to two subjects by requiring both CF-ICA positivity and GAD6s autoantibody positivity. Although analysis of GAD65 antibodies in 2805 sera was not possible by the current methodology, the presence of GAD65 antibodies in 1 of 100 individuals randomly selected from among the ICA-negative subjects, who did not develop IDDM. confirms earlier data on the prevalence of these antibodies in healthy individuals [45] . A prevalence of 1% is however 3-4 fold higher than the cumulative incidence of IDDM in The Netherlands suggesting that a positive test for GAD65 antibodies alone, measured by current methods, is not sufficient to accurately predict the clinical onset of disease within a period of 11.5 years.
This study has confirmed the early appearance of GAD65 autoantibodies in a non-familial study. The antibodies were detected in five individuals in a single serum sample obtained 3.5-7 years before clinical onset of IDDM. None of these subjects had a first-degree family member with IDDM or non-IDDM. Amongst the three CF-ICA-negative individuals who developed IDDM, one was positive for GAD65 antibodies at baseline and in 1989, which was 3.5 years before and 9.5 years after clinical onset, respectively. The increase in sensitivity of the single GAD65 antibody test compared to the double antibody test was however counterbalanced by a decrease in specificity. It is possible that the predictive value of a test for GAD65 autoantibodies alone can be increased by introducing different GAD6s antibody specificities. Recent studies have identified conformational epitopes associated with IDDM [19] , linear epitopes specific for patients with stiff-man syndrome [12] , and a linear epitope associated with protection against disease [46] in the GAD65 molecule. Assays that distinguish GAD65 antibodies of different epitope specificity may therefore be the next candidates for predictive tests. Alternatively, a combination of a test for GAD6~ antibodies for high sensitivity and early detection, and a test for antibodies that appear late in beta-cell destruction, and may be indicative of massive loss of beta cells, may provide a better predictive value. A candidate for the latter test are the 37 kDa antibodies described by Christie et al. [47] . Finally since beta-cell destruction in humans is likely to be T-cell mediated as in the animal models, [1] and antibodies may not have a direct pathogenic role, the predictive value of antibody tests may always have the limitations of an indirect parameter. It is certainly conceivable that an autoimmune response induced to an antigenic epitope in a particular HLA-background is dominated by cytotoxic T cells and massive beta-cell destruction whereas the response to other epitopes in the same molecule in the same or different HLA-haplotype is restricted to antibodies and compatible with an intact or only minor loss of beta-cell mass.
In the absence of a direct test for beta-cell destruction, a combination of a positive test for CF-ICA and GAD6s autoantibodies together with HLA-typing may provide the most accurate predictive test currently available. In this regard it is notable however that subject number 5, who has been positive for CF-ICA and GADt~ antibodies for more than 12 years, has the HLA-DR3, DQw2 and DR4,DQw8 haplotype, which confers the highest known relative risk of IDDM [7] . Thus, even this high risk MHC allele in conjunction with both CF-ICA and GAD65 autoantibodies is still not sufficient to rapidly induce the onset of IDDM.
Both CF-ICA, IAA, and GAD65 antibodies were absent at baseline in two individuals who later developed IDDM. It is not known whether antibodies never developed in these individuals or whether antibody-positive periods were missed by the single sampling at baseline. Population studies employing regular sampling of sera over 10-20 years are clearly needed to assess the full value of antibody testing in predicting IDDM, and in particular to assess whether some individuals mount an autoimmune response which is restricted to T cells, or alternatively, experience a beta-cell destruction which is not of autoimmune aetiology.
